Multiplex Assay Kit for Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay)

IBP2; IGF-BP53

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 89-99 94
EDTA plasma(n=5) 82-92 87
heparin plasma(n=5) 80-92 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 98-105% 82-101% 78-103% 97-105%
EDTA plasma(n=5) 80-97% 81-88% 98-105% 82-102%
heparin plasma(n=5) 78-105% 80-98% 86-93% 78-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:IGFBP2) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
British journal of cancer A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. pubmed:28664912
Experimental and Therapeutic Medicine Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D‑LC‑MS/MS Doi: 10.3892/etm.2018.6818
Nutrition and Cancer Serum IGFBP2 Level Is a New Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer Pubmed: 32286106
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPA053Ra01 Recombinant Insulin Like Growth Factor Binding Protein 2 (IGFBP2) Positive Control; Immunogen; SDS-PAGE; WB.
PAA053Ra01 Polyclonal Antibody to Insulin Like Growth Factor Binding Protein 2 (IGFBP2) WB; IHC; ICC; IP.
LAA053Ra81 FITC-Linked Polyclonal Antibody to Insulin Like Growth Factor Binding Protein 2 (IGFBP2) WB; IHC; ICC; IF.
LAA053Ra71 Biotin-Linked Polyclonal Antibody to Insulin Like Growth Factor Binding Protein 2 (IGFBP2) WB; IHC; ICC.
MAA053Ra21 Monoclonal Antibody to Insulin Like Growth Factor Binding Protein 2 (IGFBP2) WB; IHC; ICC; IP.
SEA053Ra ELISA Kit for Insulin Like Growth Factor Binding Protein 2 (IGFBP2) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA053Ra Multiplex Assay Kit for Insulin Like Growth Factor Binding Protein 2 (IGFBP2) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.